Metformin enhanced in vitro radiosensitivity associates with G2/M cell cycle arrest and elevated adenosine-5’-monophosphate-activated protein kinase levels in glioblastoma
, , , , , , , , , , and | Nov 01, 2017
About this article
Article Category: Research Article
Published Online: Nov 01, 2017
Page range: 431 - 437
Received: Feb 12, 2017
Accepted: Sep 30, 2017
DOI: https://doi.org/10.1515/raon-2017-0042
© 2017 Sebastian Adeberg, Denise Bernhardt, Semi B. Harrabi, Nils H. Nicolay, Juliane Hörner-Rieber, Laila König, Michael Repka, Angela Mohr, Amir Abdollahi, Klaus-Josef Weber, Juergen Debus, Stefan Rieken
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sebastian Adeberg
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Clinical Cooperation Unit Radiation Oncology,
German Cancer Research Center (DKFZ)
Heidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Denise Bernhardt
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Semi B. Harrabi
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Nils H. Nicolay
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Clinical Cooperation Unit Radiation Oncology,
German Cancer Research Center (DKFZ)
Heidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Juliane Hörner-Rieber
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Laila König
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Michael Repka
Department of Radiation Medicine,
Georgetown University HospitalWashington DC, USA
Angela Mohr
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Amir Abdollahi
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Tanslational Radiation Oncology, German Cancer Consortium (DKTK)
National Center for Tumor Diseases German Cancer Research Center (DKFZ)Heidelberg, Germany
Klaus-Josef Weber
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Juergen Debus
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Clinical Cooperation Unit Radiation Oncology,
German Cancer Research Center (DKFZ)
Heidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany
Stefan Rieken
University Hospital of Heidelberg,
Department of Radiation OncologyHeidelberg, Germany
Heidelberg Ion-Beam Therapy Center (HIT)Heidelberg, Germany
Heidelberg Institute for Radiation Oncology
University Hospital of HeidelbergHeidelberg, Germany